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The diagnosis of Multiple Myeloma is a challenge to the physician due to the non-speciﬁc
symptoms (anemia, bone pain and recurrent infections) that are commonplace in the elderly
population. However, early diagnosis is associated with less severe disease, including fewer
patients presenting with acute renal injury, pathological fractures and severe anemia. Since
2006,  the serum free light chain test Freelite® has been included alongside standard labora-
tory  tests (serum and urine protein electrophoresis, and serum and urine immunoﬁxation)
as  an aid in the identiﬁcation of monoclonal proteins, which are a cornerstone for the
diagnosis of Multiple Myeloma. The serum free light chain assay recognizes the light chain
component of the immunoglobulin in its free form with high sensitivity. Other assays that
measure light chains in the free and intact immunoglobulin forms are sensitive, but unfor-
tunately, due to the nomenclature used, these assays (total light chains) are sometimes used
in  place of the free light chain assay. This paper reviews the available literature comparing
the two assays and tries to clarify hypothetical limitations of the total assay to detect Multi-
ple  Myeloma. Furthermore, we elaborate on our study comparing the two assays used in 11
Light Chain Multiple Myeloma patients at presentation and 103 patients taken through the
course of their disease. The aim of this article is to provide a clear discrimination between
the two assays and to provide information to physicians and laboratory technicians so that
they  can utilize the International Myeloma Working Group guidelines.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
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cations which led to its inclusion in different international
guidelines.13
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Figure 1 – A diagram of intact immunoglobulin showing38  rev bras hematol he
Introduction
Monoclonal Gammopathies (MGs) include premalignant Mon-
oclonal Gammopathies of Uncertain Signiﬁcance (MGUS),
Smoldering/Indolent Multiple Myeloma  and malignant [Soli-
tary Plasmocytoma, Multiple Myeloma  (MM), Light Chain
Amyloidosis or Waldenstrom’s Macroglobulinemia (WM)] con-
ditions. These disorders are commonly characterized by the
production of monoclonal proteins which may be either intact
immunoglobulins (M-Ig), serum free light chains (sFLC), a com-
bination of both, or rarely, free heavy chains only.1,2 A low
percentage of these disorders present without the production
of any monoclonal protein.
The asymptomatic disorders are identiﬁed through routine
laboratory investigations, whilst the diagnosis of the symp-
tomatic disorders can present considerable difﬁculties to the
physician as the symptoms (anemia, recurrent infections,
fatigue and bone pain) are common in elderly populations
and are not speciﬁc to the disease.3–5 However, there is a
need for timely diagnosis as delays can lead to an increased
severity of the disease, including acute renal failure and
pathological fractures, which can result in a shorter overall
survival.6
Immunoglobulin  structure  and  sequence
variation
Immunoglobulins are the soluble, secreted form of the B-cell
receptor and are composed of repeating mirror images com-
prising two identical heavy chains (gamma  – , alpha – , mu –
, delta –  or epsilon – ) and two identical light chains (kappa –
 or lambda – ). Immunoglobulin heavy and light chains each
have constant and variable regions. A pair of heavy and light
chain variable regions together forms the antigen-binding
site. The variable regions exhibit enormous structural diver-
sity, particularly of antigen-binding contacts, allowing the
recognition of a huge variety of antigens.
In humans, it is calculated that there are at least 1011
possible antibody structural variants, which allows for the
recognition of a vast number of different antigens.7 The diver-
sity is generated in four main ways.
Firstly, different combinations of gene segments are used
in the rearrangement of heavy and light chain genes during
early B-cell development. Kappa light chains are constructed
from one of approximately 40 functional variable (V) gene
segments, one of 5 joining (J) gene segments and a single
constant (C) gene. Lambda light chains are constructed from
one of approximately 30 variable (V) gene segments, and one
of four (or more)  pairs of functional joining (J) gene segments
and constant (C) genes.7 The heavy chain variable region is
formed from one of around 60 variable (VH), one of 30 diversity
(DH), and one of six joining (JH) gene segments.7 This combina-
tional diversity accounts for a substantial amount of variable
region diversity. Secondly, diversity arises from the addition
or removal of nucleotides at the junctions between V (D) and J
gene segments during recombination. A third source of diver-
sity arises from the many  different combinations of heavy and
light chains, and ﬁnally, somatic hypermutation introducesr. 2 0 1 6;3 8(1):37–43
point mutations in the variable region genes of light and heavy
chains in mature activated B-cells.7
In light chains, variations are also found in a region of the
variable domain corresponding to the ﬁrst 23 amino acids of
the ﬁrst framework region (a region not associated with anti-
gen binding). Using monoclonal antibodies, four  (V I − V
IV) and six  subgroups (V I − V VI) have been identiﬁed.8
Such diversity is best identiﬁed using polyclonal antibodies
that can recognize an extensive range of different epitopes.
Introduction  to  Freelite®
Freelite® (The Binding Site, UK) is the only nephelo-
metric/turbidimetric assay cleared by the Food and Drug
Administration (FDA) of the United States of America for
the measurement of serum FLC (sFLC). It uses polyclonal
antibodies produced in sheep that speciﬁcally recognize and
quantify the kappa () and lambda () sFLC separately, enabling
calculation of the kappa/lambda sFLC ratio (rFLC) which can
be used to determine clonality.9,10 The antibodies speciﬁcally
recognize epitopes present in the constant region of the light
chains, which are hidden when joined to a heavy chain part-
ner (i.e. in the form of the intact immunoglobulin) but are
exposed when the light chains are in their free form (Figure 1).
The sensitivity of assays has allowed quantiﬁcation of normal
circulating sFLC concentrations for the ﬁrst time [Reference
intervals:  – median 7.3 mg/L (95th percentile: 3.3–19.4 mg/L);
 – median 12.4 mg/L (95th percentile: 5.7–26.3 mg/L); rFLC
is 0.26–1.65].10,11 The majority of results of plasma cell
dyscrasias show increased production of either the  or  sFLC.
Individuals who have rFLC values >1.65 may have a mono-
clonal  sFLC and those with rFLC values <0.26 may have a
monoclonal  FLC.12 The applicability of the rFLC in the clin-
ical practice has been proven by a number of scientiﬁc publi-the structure of the heavy and light chains. Diagram of the
kappa () and lambda () free light chains (FLC) showing the
different domains of the light chains and the antibody target
that are recognized by the serum free light chain assay.
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urrent  techniques  used  for  the  detection  of
onoclonal  proteins
erum protein electrophoresis (SPEP) is routinely used to iden-
ify and quantify intact M-Ig, with immunoﬁxation used to
lassify according to the heavy chain (, , ,  and ) and light
hain ( or ) isotypes.8 Whilst this technique is adequate for
ost, grossly elevated intact M-Igs, sensitivity can be limited
ue to co-migration and at low serum concentrations. Fur-
hermore, SPEP poorly identiﬁes sFLC14 meaning the assay is
nadequate for the detection and quantitation of paraproteins
roduced in light chain MM or Amyloidosis.15 Historically, 24-
our urine collection has been recommended for the detection
f immunoglobulin free light chains, however there is often
oor compliance16–18 and renal function can heavily inﬂuence
he accuracy of the results.19
ifferences  between  free  light  chain  and  total
ight  chain  assays  (hypothetical)
he use of the Freelite assays in the diagnosis of MGs has
een well established.13 However there is often confusion
etween Freelite and similarly named assays which determine
he total light chain concentration in serum and urine. The
otal light chain assay measures the concentration of all anti-
odies and free light chains of a particular light chain class i.e.
gG- + IgA- + IgM- + IgD- + IgE- + free . Freelite measures
nly the free form of the light chain (free  in our example –
igure 2). Due to the difference in speciﬁcity of the assays,
otal light chain assays identify the light chain component
f intact immunoglobulins and free light chains in serum
hereas Freelite recognizes only the free light chain com-
onent. Therefore, there is a large difference in sensitivity
Measured by total light
chain assays
Measured by free light
chain assays
IgG
IgM
FLC kappa FLC lambda
FLC lambda
FLC kappa
IgA
IgE IgD
igure 2 – Measurement of kappa () and lambda () light
hains in free and total assays. Total light chain assays
easure light chains when bound to heavy chains in intact
mmunoglobulins plus free light chains (FLC). The free light
hain assay measures only free light chains.
igure adapted from Beckman Coulter Immage Systems
hemistry plan, November 2007.2 0 1 6;3 8(1):37–43 39
(Table 1) between the two assays. The presence of a poly-
clonal background prevents the total immunoglobulin assay
from being able to distinguish clonality at <4 g/L, whereas the
Freelite assay can detect clonality at mg/L concentrations.
Differences  between  the  Freelite  and  total  light
chain  assays  (data)
Recently, Hungria et al.20 published a study comparing the
sensitivity of the sFLC assays to the total light chain assays for
samples obtained from 114 light chain MM (LCMM)  patients
taken through the course of their disease. In keeping with
previous reports15,19,21–34 the FLC identiﬁed clonality in 11/11
samples at presentation and identiﬁed persistent disease in
80/103 samples taken throughout the course of the disease. In
contrast, the total light chain assay identiﬁed only 2/11 sam-
ples at presentation and 25/103 samples taken throughout the
course of the disease. Somewhat confusingly, the light chain
isotype was misreported in 11 samples as the opposite light
chain.
The International Myeloma  Working Group (IMWG) guide-
lines for the identiﬁcation of monoclonal immunoglobulins
at presentation recommend an algorithm of Freelite + SPEP
(Table 2). Hungria et al. showed that, in this study, 11/11
patients were identiﬁed using the Freelite assay and there was
no need for SPEP. In contrast, total light chain + SPEP identiﬁed
only 8/11 samples, clearly highlighting the lack of sensitiv-
ity of this algorithm recommended by the IMWG  guidelines
(Figure 3).
The sensitivity of total / and sFLC assays were compared
in a study by Marien et al.35 Sixteen serum samples from
LCMM patients were investigated. Total  and  concentra-
tions were measured using Beckman-Coulter reagents on the
IMMAGE® nephelometer and sFLC concentrations were mea-
sured by Freelite assays (The Binding Site). All samples were
abnormal by sFLC assays compared to only ﬁve of the 16 sam-
ples by total  and  assays. In addition, one  patient was
mistyped as  by the total light chain assay. Other studies have
conﬁrmed that total light chain assays are less sensitive than
sFLC analysis for the diagnosis of LCMM,  Non-secretory MM
and Amyloidosis.36–38
Summary  of  the  importance  of  the  serum  free
light  chain  assay  screening
The IMWG concluded that, for the purpose of screening for all
MGs  (with the exception of Amyloidosis), Freelite can replace
24-hour urine assessments.13 Furthermore, Katzmann et al.39
concluded that Freelite costs approximately half as much as
24-hour urine assessment based upon Medicare, USA 2006
reimbursement values.
Recently the IMWG updated the deﬁnition of MM to include
additional, validated biomarkers alongside CRAB (hypercal-
cemia, renal failure, anemia, and bone lesions) assessments.
A rFLC ≥100, with an involved free light chain concentra-
tion of >100 mg/L was included in this validated biomarker
list.40
40  rev bras hematol hemoter. 2 0 1 6;3 8(1):37–43
Table 1 – Reference intervals and lower limits of sensitivity of free light chain assays and total light chain assays in
serum.
Parameter Kappa reference interval
(mg/L)
Kappa sensitivity
(mg/L)
Lambda reference interval
(mg/L)
Lambda sensitivity
(mg/L)
Free light chains (The Binding Site) 3.3–19.4 0.3 5.7–26.3 0.4
Total light chains (Beckman Coulter) 6290–13500 111 3130–7230 300
Total light chains (Roche) 1380–3750 300 930–2420 300
100 000
100.00
1000
100
10
100.00
1000
100
10
1
0.1
0.1 1 10 100
κFLC (mg/L)
κTLC (mg/dL)
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 (m
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Figure 3 – Scatter charts showing the differences in sensitivity between the Freelite® and total light chain assays for light
chain myeloma patients taken at presentation (n = 11) and through the course of their disease (n = 103) compared to a 100
percentile normal range indicated by parallel lines. FLC: free light chain; SPE: serum protein electrophoresis; PPV: positive
predictive value; NPV: negative predictive value.
rev bras hematol hemoter. 2 0 1 6;3 8(1):37–43 41
Table 2 – International Myeloma  Working Group recommendations.
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ematological  response
nternational guidelines have included Freelite assessments
s the most effective monitoring tool in patients with
myloidosis.41,42 More  recently, new response criteria were
eﬁned based upon changes in Freelite values during
reatment.43 The response criteria utilized the rFLC and the
ifference between involved and uninvolved free light chains
dFLC); importantly the depth of the assigned response corre-
ated to overall survival.
The IMWG  recommend Freelite as the only available and
eliable method for the determination of response in patients
ith Non-secretory and Oligosecretory MM.13 More recently
n LCMM,  comparisons of response assessment as determined
y 24-hour urine evaluation and Freelite have suggested that
reelite is far superior to the 24-hour urine exam as a tool to
easure patient response (Table 2).44
In all MM patients, normalization of the Freelite ratio
orresponds to superior outcome independently of overall
esponse.45 The IMWG have reﬁned the deﬁnition of complete
esponse, (i) negative immunoﬁxation in serum and urine,
ii) disappearance of plasmacytomas, and (iii) bone marrow
nﬁltration of plasma cells below 5%, to include a normal Freel-
te ratio.46 The new response deﬁnition, stringent complete
esponse (sCR) relies on a normal Freelite ratio and nega-
ive plasma cell evaluation, and corresponds to an improved
verall survival.47
onclusions
arly detection of patients with MM is key to a reduction in
omorbidities that can impact the quality and duration of
ife. The sFLC assay, but not the total light chain assay, is
n important part of the routine laboratory test algorithm
hat contributes to the identiﬁcation of patients with MGs,
ncluding MM.  To date, there are two pivotal studies that
ighlight the limited utility of the total light chain assay in
he detection of MGs. In the study presented by Hungria et al.,ation; LCE: light chain escape; sFLCs: Serum free light chains.
the addition of total light chain to SPEP failed to identify all
LCMM patients, highlighting an important insensitivity when
utilizing this assay. Similar results were reported by Marien
et al. The assays can be easily distinguished based upon their
normal ranges and caution is urged to utilize the sFLC assay,
but not the total light chain assay for the screening, diagnosis
and hematological responses in MGs.
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